Kathleen Moore to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Kathleen Moore has written about Xenograft Model Antitumor Assays.
Connection Strength
0.072
-
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
Score: 0.038
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.034